[go: up one dir, main page]

MX2019008317A - Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico. - Google Patents

Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Info

Publication number
MX2019008317A
MX2019008317A MX2019008317A MX2019008317A MX2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A
Authority
MX
Mexico
Prior art keywords
liver disease
fatty liver
nonalcoholic fatty
prophylactic
therapeutic drug
Prior art date
Application number
MX2019008317A
Other languages
English (en)
Inventor
Sasaki Yusuke
Tanaka Toshiya
ASAHIYAMA Masato
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2019008317A publication Critical patent/MX2019008317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención aborda el problema de proporcionar una composición medicinal y una combinación de fármacos mediante la cual puede prevenirse y/o tratarse enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica. La presente invención proporciona una combinación de un agonista de receptor activado por proliferador de peroxisoma a con un inhibidor de cotransportador 2 de glucosa de sodio (SGLT2), la cual va a ser usada para prevenir y/o tratar enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica.
MX2019008317A 2017-01-11 2018-01-11 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico. MX2019008317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017002731 2017-01-11
PCT/JP2018/000398 WO2018131626A1 (ja) 2017-01-11 2018-01-11 非アルコール性脂肪性肝疾患の予防及び治療薬

Publications (1)

Publication Number Publication Date
MX2019008317A true MX2019008317A (es) 2019-09-19

Family

ID=62840012

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008317A MX2019008317A (es) 2017-01-11 2018-01-11 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
MX2022015500A MX2022015500A (es) 2017-01-11 2019-07-10 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015500A MX2022015500A (es) 2017-01-11 2019-07-10 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Country Status (13)

Country Link
US (3) US20200022960A1 (es)
EP (1) EP3569250B1 (es)
JP (3) JP7202892B2 (es)
KR (1) KR102487075B1 (es)
CN (1) CN110167595A (es)
AU (1) AU2018206907B2 (es)
CA (1) CA3047716A1 (es)
ES (1) ES3026786T3 (es)
HU (1) HUE071625T2 (es)
MX (2) MX2019008317A (es)
PL (1) PL3569250T3 (es)
RS (1) RS66854B1 (es)
WO (1) WO2018131626A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
MX2021008010A (es) * 2018-12-31 2021-10-13 Coherus Biosciences Inc Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
WO2020205027A1 (en) * 2019-04-02 2020-10-08 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
IL293894A (en) * 2019-12-20 2022-08-01 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
US20240277745A1 (en) 2021-05-27 2024-08-22 Kowa Company, Ltd Pemafibrate and/or tofogliflozin for use in treating liver disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI309980B (en) 2003-03-14 2009-05-21 Yamanouchi Pharma Co Ltd C-glycoside derivatives or salts thereof
KR100515360B1 (ko) 2003-09-02 2005-09-15 삼성에스디아이 주식회사 플라즈마 표시 패널 및 그의 구동 방법
WO2005023777A1 (ja) 2003-09-03 2005-03-17 Kowa Co., Ltd. Ppar活性化化合物及びこれを含有する医薬組成物
WO2006009149A1 (ja) * 2004-07-21 2006-01-26 Kissei Pharmaceutical Co., Ltd. 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
KR20150005365A (ko) 2013-07-05 2015-01-14 에스케이하이닉스 주식회사 주기신호생성회로
TWI696462B (zh) 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
JP2017528499A (ja) 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤

Also Published As

Publication number Publication date
EP3569250A1 (en) 2019-11-20
EP3569250A4 (en) 2020-11-04
KR102487075B1 (ko) 2023-01-09
EP3569250C0 (en) 2025-04-30
JP2023024728A (ja) 2023-02-16
RU2019123735A (ru) 2021-02-12
ES3026786T3 (en) 2025-06-12
EP3569250B1 (en) 2025-04-30
RU2019123735A3 (es) 2021-03-26
BR112019013539A2 (pt) 2020-01-07
JP2024177232A (ja) 2024-12-19
AU2018206907A1 (en) 2019-07-11
WO2018131626A1 (ja) 2018-07-19
JP7202892B2 (ja) 2023-01-12
MX2022015500A (es) 2023-01-24
CN110167595A (zh) 2019-08-23
US20200022960A1 (en) 2020-01-23
US20220054459A1 (en) 2022-02-24
PL3569250T3 (pl) 2025-06-23
HUE071625T2 (hu) 2025-09-28
US20240325356A1 (en) 2024-10-03
AU2018206907B2 (en) 2023-11-02
US12042483B2 (en) 2024-07-23
KR20190104542A (ko) 2019-09-10
RS66854B1 (sr) 2025-06-30
JPWO2018131626A1 (ja) 2019-11-07
CA3047716A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
MX2022015500A (es) Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
AR071003A1 (es) Farmaco contra cancer de higado
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
PH12021500012A1 (en) Inhibitors of keapi-nrf2 protein-protein interaction
AU2018246796A1 (en) S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MA39443A1 (fr) Nouvelle formulation de méloxicam
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX2021000700A (es) Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica.
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
EP3650029A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY WITH ADENOSINE DERIVATIVE
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MY196680A (en) Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2- pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3- quinolinecarboxamide